KALA BIO Gestione

Gestione criteri di controllo 2/4

KALA BIO Il CEO è Mark Iwicki, nominato in Sep2015, e ha un mandato di 9.17 anni. la retribuzione annua totale è $ 8.34M, composta da 8.5% di stipendio e 91.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.57% delle azioni della società, per un valore di $ 492.30K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 6.5 anni e 7.2 anni.

Informazioni chiave

Mark Iwicki

Amministratore delegato

US$8.3m

Compenso totale

Percentuale dello stipendio del CEO	8.5%
Mandato del CEO	9.2yrs
Proprietà del CEO	1.6%
Durata media del management	6.5yrs
Durata media del Consiglio di amministrazione	7.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mark Iwicki rispetto agli utili di KALA BIO?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	-US$39m
Jun 30 2024	n/a	n/a	-US$39m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$8m	US$709k	-US$42m
Sep 30 2023	n/a	n/a	-US$46m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$2m	US$682k	-US$45m
Sep 30 2022	n/a	n/a	-US$80m
Jun 30 2022	n/a	n/a	-US$137m
Mar 31 2022	n/a	n/a	-US$145m
Dec 31 2021	US$3m	US$644k	-US$143m
Sep 30 2021	n/a	n/a	-US$126m
Jun 30 2021	n/a	n/a	-US$126m
Mar 31 2021	n/a	n/a	-US$113m
Dec 31 2020	US$5m	US$586k	-US$104m
Sep 30 2020	n/a	n/a	-US$95m
Jun 30 2020	n/a	n/a	-US$90m
Mar 31 2020	n/a	n/a	-US$91m
Dec 31 2019	US$3m	US$564k	-US$94m
Sep 30 2019	n/a	n/a	-US$98m
Jun 30 2019	n/a	n/a	-US$90m
Mar 31 2019	n/a	n/a	-US$81m
Dec 31 2018	US$3m	US$535k	-US$67m
Sep 30 2018	n/a	n/a	-US$53m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$44m
Dec 31 2017	US$2m	US$501k	-US$42m

Compensazione vs Mercato: La retribuzione totale di Mark ($USD 8.34M ) è superiore alla media delle aziende di dimensioni simili nel mercato UK ($USD 354.03K ).

Compensazione vs guadagni: La retribuzione di Mark è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Mark Iwicki (58 yo)

9.2yrs

Mandato

US$8,342,714

Compensazione

Mr. Mark T. Iwicki has been Director at Q32 Bio Inc since March 2023. Mr. Iwicki previously served as the Chairman of Legacy Q32’s board of directors since 2020. He had been Chairman of Aerovate Therapeuti...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Iwicki	Chairman & CEO	9.2yrs	US$8.34m	1.57% $ 492.3k
Todd Bazemore	President & COO	7yrs	US$2.94m	0.49% $ 152.1k
R. Brazzell	Head of R&D and Chief Medical Officer	11.8yrs	US$2.92m	0.54% $ 167.8k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Mary Reumuth	CFO & Treasurer	10.8yrs	Nessun dato	0.35% $ 109.1k
Jill Steier	Executive Director of Investor Relations & Corporate Communications	3.3yrs	Nessun dato	Nessun dato
Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	7.3yrs	Nessun dato	Nessun dato
Darius Kharabi	Chief Business Officer	3yrs	Nessun dato	0.48% $ 150.5k
Francis Mah	Chief Medical Advisor	1.7yrs	Nessun dato	Nessun dato
Josiah Craver	Senior VP & Corporate Controller	2.6yrs	Nessun dato	Nessun dato
Carl Rennie	Executive Director of Account Management	6.5yrs	Nessun dato	Nessun dato
Patrick Bedell	Executive Director of Trade & Alternate Channels	6.5yrs	Nessun dato	Nessun dato

6.5yrs

Durata media

56yo

Età media

Gestione esperta: Il team dirigenziale di 0JQ2 è esperto e expertise (durata media dell'incarico 6.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mark Iwicki	Chairman & CEO	9.6yrs	US$8.34m	1.57% $ 492.3k
Justin Hanes	Founder & Chair of the Scientific Advisory Board	no data	Nessun dato	Nessun dato
Jonathan Silverstein	Board Observer	8.6yrs	Nessun dato	Nessun dato
Gregory Perry	Independent Director	6.8yrs	US$302.01k	0.051% $ 16.1k
Peter Hutt	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Andrew Koven	Lead Independent Director	7.2yrs	US$402.36k	0.066% $ 20.8k
Ronald Krall	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Bennett Shapiro	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Colin Gardner	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Charles Myers	Independent Director	3.1yrs	US$236.94k	0.029% $ 9.0k
Howard Rosen	Independent Director & Member of Advisory Board	10.8yrs	US$392.20k	0.065% $ 20.5k
Marjan Farid	Independent Director	2.1yrs	US$225.64k	0.024% $ 7.5k

7.2yrs

Durata media

66yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 0JQ2 sono considerati esperti (durata media dell'incarico 7.2 anni).

KALA BIO Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Insufficient new directors

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Recent updates

New major risk - Shareholder dilution

KALA BIO, Inc. announced that it has received $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc. announced that it expects to receive $12.499192 million in funding from Baker Bros. Advisors LP, ADAR1 Capital Management, LLC, SR One Capital Management, LP

KALA BIO, Inc., Annual General Meeting, Jun 11, 2024

KALA BIO, Inc. announced that it expects to receive $8.599799 million in funding from Baker Bros. Advisors LP

KALA BIO, Inc. announced that it expects to receive $1.999824 million in funding

New major risk - Revenue size

First half 2023 earnings released: US$11.35 loss per share (vs US$41.26 loss in 1H 2022)

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 22, 2023

First quarter 2023 earnings released: US$6.99 loss per share (vs US$22.37 loss in 1Q 2022)

Full year 2022 earnings released: US$29.48 loss per share (vs US$109 loss in FY 2021)

Kala Pharmaceuticals, Inc. announced that it has received $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED

Kala Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

Kala Pharmaceuticals, Inc. announced that it expects to receive $30.999475 million in funding from Baker Bros. Advisors LP

Kala Pharmaceuticals, Inc. Announces Appointment of Marjan Farid to Its Board of Directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.38 loss per share (vs US$0.56 loss in 2Q 2021)

Kala Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Kala Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

Alcon Pharmaceuticals Ltd and Alcon Vision, LLC completed the acquisition of EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA).

Insufficient new directors

Kala Pharmaceuticals Receives Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Alcon Inc. (SWX:ALC) entered into a agreement to acquire EYSUVIS® and certain assets of Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $385 million.

Alcon Inc. (SWX:ALC) acquired EYSUVIS® from Kala Pharmaceuticals, Inc. (NasdaqGS:KALA) for $60 million.

First quarter 2022 earnings released: US$0.45 loss per share (vs US$0.49 loss in 1Q 2021)

Kala Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting

Kala Pharmaceuticals, Inc., Annual General Meeting, Jun 16, 2022

Insufficient new directors

Full year 2021 earnings released: US$2.19 loss per share (vs US$1.99 loss in FY 2020)

Insufficient new directors

Third quarter 2021 earnings released: US$0.43 loss per share (vs US$0.50 loss in 3Q 2020)

No longer forecast to breakeven

Second quarter 2021 earnings released: US$0.56 loss per share (vs US$0.42 loss in 2Q 2020)

Insufficient new directors

Insufficient new directors

First quarter 2021 earnings released: US$0.49 loss per share (vs US$0.54 loss in 1Q 2020)

Kala Pharmaceuticals Announces Preferred Position for Eysuvis™ on Cigna

New 90-day low: US$6.86

Full year 2020 earnings released: US$1.99 loss per share (vs US$2.76 loss in FY 2019)

Revenue misses expectations

Kala Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Kala Pharmaceuticals Announces EYSUVIS™ Now Covered by Express Scripts

Kala Pharmaceuticals, Inc. Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media